- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Regorafenib has a clear use of the "red line". The following two groups of people belong to the category of absolute or relative contraindicati...
Targeted drug regorafenib often accompanies adverse reactions in treatment, among which fatigue, stomatitis, and decreased appetite have the gr...
During the treatment with adatinib, diarrhea, fatigue, and dry skin are common adverse reactions that affect quality of life. Proactively manag...
The use of adatinib requires strict screening of the appropriate population, and some patients may face higher risks due to their underlying co...
During the treatment with adatinib, hyperphosphatemia, stomatitis, nail dissection, and ocular toxicity are four adverse reactions that require...
Edatinib is an oral FGFR kinase inhibitor used to treat locally advanced or metastatic urothelial carcinoma carrying FGFR2/3 gene mutations. Ac...
Elafibrino should be strictly used under the guidance of a doctor, and correctly mastering the usage and dosage, understanding the efficacy eva...
During the use of Elafiprono, it is necessary to closely monitor creatinine levels, weight changes, and the risk of concomitant medication. Sci...
Elafiber poses serious safety risks in specific populations, especially for patients with severe liver dysfunction and biliary obstruction, and...
Itching, nausea, and fatigue are common discomforts during the treatment of Eilafilano. Scientific management can improve the quality of life, ...
